Canada Approves Vertex’s Kalydeco (JNJ) (VRTX)
Vertex Pharmaceuticals Incorporated ( VRTX ) recently announced the approval of its cystic fibrosis (CF) treatment, Kalydeco, in Canada. Kalydeco gained approval for the treatment of cystic fibrosis in patients aged 6 years and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Kalydeco is already approved in the US and the EU. […]